0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.
① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.
It's adding insult to injury! JiangSu WuZhong Pharmaceutical Development is beset by three major Bearish factors. Will the agency rights for Tongyan needles change? | Quick Announcement
① JiangSu WuZhong Pharmaceutical Development is currently facing uncertainties such as allegations of violating information disclosure laws, subsidiary's alleged assistance in tax fraud, and changes in agency rights for AestheFill within China. ② Compared to the beginning of the year, the company's stock price has fallen over 35%, reaching a new low for this year.
The "hot battle" of humanoid robots has begun: frequent release of new products. Is the year of mass production really here? | Industry observation
① Siasun Robot&Automation and Zhiyuan Robot both launched new humanoid robots, and related Concept stocks rose in response; ② mass production of humanoid robots still faces challenges, and domestic manufacturers aim to produce thousands of units this year; ③ there are also disputes within the Industry regarding the implementation scenarios.
JiangSu WuZhong Pharmaceutical Development is in trouble! A subsidiary has been sued for assisting in a tax fraud case and is also under investigation for violation of information disclosure regulations.
① JiangSu WuZhong Pharmaceutical Development announced that its subsidiary and the Chairman are being prosecuted for assisting in tax fraud of 0.242 billion yuan, and are also being investigated by the Securities Regulatory Commission for information disclosure violations, which may pose a risk of (Delisted); ② although the two incidents are closely timed, legal experts say that no correlation can be discerned at present; ③ since the third quarter of last year, JiangSu WuZhong's performance has shown significant improvement; ④ some investors have declared "they will protect their legitimate rights and interests" due to the significant fluctuations in stock prices.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
JiangSu WuZhong Pharmaceutical Development is suspected of violations related to information disclosure and has been filed for investigation after years of losses, just turning a profit.|Brief Announcement
① JiangSu WuZhong Pharmaceutical Development has been put under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws; ② The company has reported a net income loss for six consecutive years, yet aims to turn a profit in 2024 by focusing on a single product in the medical aesthetics sector; ③ Previously, the company faced several instances of being penalized for various legal violations, but none have occurred in the last three years.